Wednesday, June 10, 2026
🇺🇸 FDA

pharma · TTR-mediated Amyloidosis · Hypertension · ALNY

Alnylam Netherlands

Alnylam Netherlands B.V.

Alnylam Netherlands patent portfolio — 379 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Cambridge, USA HQ
2002 Founded
2,826 Employees
Public company Type
ALNY · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Founded
2002
Employees
2,826
Programs
84
Drugs
37
Patents
379
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

Alnylam Netherlands patents

379 pharmaceutical patents indexed for Alnylam Netherlands. 4 expire within 24 months.

Alnylam Netherlands has 379 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 4 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

379 patents

Patent portfolio

Page 3 of 8

  1. US 11034958

    Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11034957

    Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11028392

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10995336

    Serpina1 iRNA compositions and methods of use thereof

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10988768

    TMPRSS6 iRNA compositions and methods of use thereof

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10982215

    Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10982212

    Conserved HBV and HCV sequences useful for gene silencing

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10968452

    Polynucleotide agents targeting aminolevulinic acid synthase-1 (ALAS1) and uses thereof

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10954516

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10946107

    Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, HAO1) and methods of use thereof

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10934544

    Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof

    Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10934545

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10933081

    Myostatin iRNA compositions and methods of use thereof

    Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10920223

    Serpina1 iRNA compositions and methods of use thereof

    Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10913950

    TMPRSS6 iRNA compositions and methods of use thereof

    Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10889813

    Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10883107

    Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10851377

    Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10844384

    Glucokinase (GCK) iRNA compositions and methods of use thereof

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10829763

    TMPRSS6 iRNA compositions and methods of use thereof

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10814007

    Angiotensinogen (AGT) iRNA compositions and methods of use thereof

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10806791

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10808246

    Oligonucleotide-ligand conjugates and process for their preparation

    Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10767177

    Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10745704

    Compositions and methods for inhibiting expression of CD274/PD-L1 gene

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10745702

    Compositions and methods for inhibiting expression of the LECT2 gene

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10709728

    Polynucleotide agents targeting angiotensinogen (AGT) and methods of use thereof

    Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10683501

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10683504

    Serpina1 iRNA compositions and methods of use thereof

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10676740

    Modified iRNA agents

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10668170

    Modified RNAi agents

    Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10669303

    Compositions and methods directed to treating liver fibrosis

    Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10669544

    Therapeutic compositions

    Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10640770

    Hepatitis D virus (HDV) iRNA compositions and methods of use thereof

    Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10612024

    Modified double-stranded RNA agents

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10612027

    Modified double-stranded RNA agents

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10597661

    Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (PNPLA3) and methods of use thereof

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10570391

    RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10570393

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10557139

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10550386

    Monomers and oligonucleotides comprising cycloaddition adduct(s)

    Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10550390

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10513703

    Hepatitis B virus (HBV) iRNA compositions and methods of use thereof

    Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10501742

    Compositions and methods for inhibiting expression of the PCSK9 gene

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10501740

    Compositions and methods for inhibiting expression of factor V

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10494632

    Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10478500

    Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression

    Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10472628

    Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene

    Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Alnylam Netherlands have?

379 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Alnylam Netherlands patents expire?

4 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.